Mutation detail:
| Mutation site | F4A |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | E |
| Gene ID | 43740570 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | YP_009724392.1 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
decrease |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Envelope Protein |
| Uniprot protein ID | P0DTC4 |
| Protein length | 75 amino acids |
| Protein description | The SARS-CoV-2 envelope (E) protein is a small structural protein involved in many aspects of the viral life cycle. The E protein promotes the packaging and reproduction of the virus, and deletion of this protein weakens or even abolishes the virulence. |
Literature information:
| Pubmed ID | 34112954 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | Cell Reports |
| Title | SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target |
| Author | Bingqing Xia, Xurui Shen, Yang He, Xiaoyan Pan, Feng-Liang Liu |
| Evidence | Among the total 70 mutants, we found that two mutants Phe4Ala (2-EF4A) and Thr11Ala (2-ET11A) significantly alleviated cell death compared with wild-type (WT, 2-E) and other mutant channels (Fig. 4a). |